Gremen Emeric, Frandon Julien, Lateur Gabriel, Finas Mathieu, Rodière Mathieu, Horteur Clément, Benassayag Michaël, Thony Frédéric, Pailhe Régis, Ghelfi Julien
Faculty of Medecine, Grenoble-Alpes University, 38043 Grenoble, France.
Radiology Department, Grenoble Alpes University Hospital, 38043 Grenoble, France.
Biomedicines. 2022 Mar 22;10(4):744. doi: 10.3390/biomedicines10040744.
Musculoskeletal (MSK) embolization is emerging in tendinopathy treatment. The objective of this study was to assess the efficacy and safety of MSK embolization with microspheres in the treatment of chronic shoulder pain.
This retrospective monocentric study included patients with chronic shoulder pain resistant to 6 months or more of conventional therapies who were treated with MSK embolization between 2017 and 2021. Embolization was performed using calibrated 100-250 µm microspheres. Clinical success was defined as pain reduction, i.e., a decrease in the visual analogue scale (VAS) pain score of ≥50% at 3 months after MSK embolization as compared to baseline. Adverse events were collected.
Fifteen patients (11 women, 4 men) were included, with a median age of 50.3 years (IQR: 46.7-54.5). The median duration of symptoms was 26.6 months (20.6-39.8). The median VAS pain scores were 7.0 (7.0-8.0) at baseline, 6.0 (3.5-7.0) at 1 month, 5.0 (4.5-6.5) and 5.0 (3.0-7.4) at 3 months and 6 months ( = 0.002). Three patients (20%) reported clinical success at 3 months. Three patients experienced minor complications after embolization (paresthesia, = 2; transient osteo-medullary edema, = 1) and two patients had moderate complications (transient skin ischemia).
MSK embolization with microspheres for treatment of refractory chronic shoulder pain showed moderate results in terms of clinical success and safety.
肌肉骨骼（MSK）栓塞术正逐渐应用于肌腱病治疗。本研究的目的是评估微球MSK栓塞术治疗慢性肩部疼痛的疗效和安全性。
这项回顾性单中心研究纳入了2017年至2021年间接受MSK栓塞术治疗的慢性肩部疼痛患者，这些患者对6个月或更长时间的传统治疗无效。使用校准的100 - 250μm微球进行栓塞。临床成功定义为疼痛减轻，即与基线相比，MSK栓塞术后3个月视觉模拟量表（VAS）疼痛评分降低≥50%。收集不良事件。
纳入15例患者（11例女性，4例男性），中位年龄50.3岁（四分位间距：46.7 - 54.5）。症状的中位持续时间为26.6个月（20.6 - 39.8）。基线时VAS疼痛评分的中位数为7.0（7.0 - 8.0），1个月时为6.0（3.5 - 7.0），3个月和6个月时分别为5.0（4.5 - 6.5）和5.0（3.0 - 7.4）（P = 0.002）。3例患者（20%）在3个月时报告临床成功。3例患者栓塞后出现轻微并发症（感觉异常，n = 2；短暂性骨骨髓水肿，n = 1），2例患者出现中度并发症（短暂性皮肤缺血）。
微球MSK栓塞术治疗难治性慢性肩部疼痛在临床成功率和安全性方面显示出中等效果。
